APLN and in situ carcinoma: The DEGs of the CIS-IRI group were mainly involved in the p53 signaling pathway, platinum drug resistance, HIF-1 signaling pathway, cell cycle, apelin signaling pathway, JAK-STAT signaling pathway, cellular senescence, and PI3K-Akt signaling pathway (Figure 4(f)).